CP2 Biotech, a startup incubated by Bio4Dreams since 2024 and specialized in developing therapeutic solutions to modulate immune and inflammatory processes, has received an investment from Bio4Dreams to accelerate the preclinical development and validation of its innovative molecules.

Founded in 2020 as a spin-off of the University of Milano-Bicocca, CP2 Biotech focuses on researching and developing molecules capable of modulating the activity of the TLR4 receptor—a key component in regulating the body’s immune and inflammatory responses. These solutions represent potential breakthrough treatments for serious conditions such as autoimmune, fibrotic, and oncological diseases.

This investment builds on the ongoing support provided through the startup’s incubation and aims to fast-track the most promising CP2 Biotech molecules toward clinical trials.

Thanks to the investment and the access to Bio4Dreams’ international network, CP2 Biotech is now better positioned to strengthen its operations and accelerate molecule validation—bringing its research one step closer to becoming real, life-changing therapies for patients.

📗 Learn more about CP2 Biotech and other companies in our portfolio.